期刊
LANCET RESPIRATORY MEDICINE
卷 9, 期 12, 页码 1450-1466出版社
ELSEVIER SCI LTD
DOI: 10.1016/S2213-2600(21)00407-0
关键词
-
资金
- Biotechnology and Biological Sciences Research Council (London Interdisciplinary Doctoral Training Programme) [BB/M009513/1]
- UK Department of Health and Social Care
Protective immune response lasts for approximately 5-12 months, making reinfection more likely. Markers of humoral and cell-mediated immune memory can persist over many months, helping to mitigate against severe disease.
Many nations are pursuing the rollout of SARS-CoV-2 vaccines as an exit strategy from unprecedented COVID-19related restrictions. However, the success of this strategy relies critically on the duration of protective immunity resulting from both natural infection and vaccination. SARS-CoV-2 infection elicits an adaptive immune response against a large breadth of viral epitopes, although the duration of the response varies with age and disease severity. Current evidence from case studies and large observational studies suggests that, consistent with research on other common respiratory viruses, a protective immunological response lasts for approximately 5-12 months from primary infection, with reinfection being more likely given an insufficiently robust primary humoral response. Markers of humoral and cell-mediated immune memory can persist over many months, and might help to mitigate against severe disease upon reinfection. Emerging data, including evidence of breakthrough infections, suggest that vaccine effectiveness might be reduced significantly against emerging variants of concern, and hence secondary vaccines will need to be developed to maintain population-level protective immunity. Nonetheless, other interventions will also be required, with further outbreaks likely to occur due to antigenic drift, selective pressures for novel variants, and global population mobility.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据